

<sup>1</sup>Eveline Kaambo, <sup>1</sup>Pedro M D S Abrantes, <sup>2</sup>Carole McArthur, <sup>1</sup>Charlene W J Africa



Department of Medical Biosciences, University of the Western Cape, Bellville 7535, Cape Town, South Africa; <sup>2</sup> Department of Oral and Craniofacial Sciences, University of Missouri-Kansas City, USA

Email: cafrica@uwc.ac.za

#### Introduction

The vaginal microbiota of a healthy asymptomatic woman consists of an extensive diversity of anaerobic and aerobic bacterial genera and species dominated by the microaerophilic genus Lactobacillus (Donati et al., 2010), known to inhibit the growth of potentially pathogenic nonacid tolerant microorganisms (Mijac et al., 2006; Li et al., 2011; Stojanovic et al., 2012). An imbalance of species within this biofilm may result in endogenous opportunistic infections such as aerobic vaginitis (AV). Streptococcus agalactiae (S. agalactiae) and Enterococcus faecalis (E. faecalis) were found to be the predominant Gram-positive cocci in AV and have been implicated in neonatal and obstetric sepsis. The prevalence and antibiotic profiles of bacteria appear to differ in different geographical locations thus complicating the standardisation of infection control.

# Objective

The aim of the study was to determine the prevalence and antimicrobial susceptibility of *E. faecalis* and *S. agalactiae* in pregnant women with AV in the Western Cape, South Africa.

# Methodology

Ano-vaginal swab samples were collected from 301 women at 28-37 weeks of gestation. Patient demography was obtained by completion of a questionnaire. The "AV" score was microscopically graded as absent, slight, moderate or severe by comparing the proportion of lactobacilli with leukocytes, other vaginal microflora and parabasal epithelial cells. Swabs were cultured by routine methods and antibiotic susceptibility profiles were determined using the Sensititre TREK system. Isolation and identification of Gram-positive cocci were achieved by conventional methods. The study complied with the Declaration of Helsinki (2013).

### Results

AV was detected in 52 of the 199 (26.13%) pregnant women, with S. agalactiae and E. faecalis isolated from 32 and 20 mothers respectively. Using EUCAST/CLSI breakpoints, S. agalactiae and E. faecalis showed resistance to 12 of the 17 antibiotics tested, including those recommended for prophylaxis according to the CDC guidelines, namely penicillin, erythromycin, cefazolin, clindamycin, tetracycline and vancomycin. Fig. 1 represents the number of women with S. agalactiae and E. faecalis expressed as a percentage of the total number of women with AV (N=79). The sensititre trek system results of the antimicrobial susceptibility analysis for both S. agalactiae and E. faecalis are shown in Table 1.




Figure 1. Frequency of *S. agalactiae* and *E. faecalis* in women with AV.

Table 1: Prevalence and susceptibility of *E. faecalis* and *S.* agalactiae isolates in pregnant mothers with AV.

ANTIMICROBIAL		Current pregnancy outcomes  Frequency (%) Frequency (%)	
		<u>E. faecalis</u> <u>isolates</u> (n = 20)	S. agalactiae isolates (n = 32)
	Susceptible	4 (20.0%)	16 (50.0%)
AZITHROMYCIN <sup>a</sup>	Intermediate Resistant	1 (5.0%) 15 (75.0%)	16 (50.0%)
	Susceptible	-	18 (56.25%)
CEFOTAXIME a	Intermediate Resistant	20 (100.0%)	14 (43.75%)
			,
CEFTRIAXONE a	Susceptible Intermediate	-	18 (56.25%)
	Resistant	20 (100.0%)	14 (43.75%)
CHLORAMPHENICOL a	Susceptible	17 (85.0%)	23 (71.9%)
	Intermediate Resistant	3 (15.0%)	9 (28.1%)
CLINDAMYCIN a	Susceptible	2 (10.0%)	18 (56.25%)
	Intermediate Resistant	5 (25.0%) 13 (65.0%)	14 (43.75%)
			,
DAPTOMYCIN a	Susceptible Intermediate	3 (15.0%)	20 (62.5%)
	Resistant	17 (85.0%)	12 (37.5%)
	Susceptible	-	19 (40.6%)
ERTAPENEM b	Intermediate Resistant	20 (100.0%)	13 (40.6%)
	O constants	0 (40 00()	10 (50 00/)
ERYTHROMYCIN a	Susceptible Intermediate	2 (10.0%) 1 (5.0%)	16 (50.0%)
	Resistant	17 (85.0%)	16 (50.0%)
LEVOFLOXACIN a	Susceptible	12 (60.0%)	24 (75.0%)
	Intermediate Resistant	2 (10.0%) 6 (30.0%)	8 (25.0%)
			100 (400 00()
LINEZOLID a	Susceptible Intermediate	17 (85.0%) 2 (10.0%)	32 (100.0%)
	Resistant	1 (5.0%)	
MEROPENEM a	Susceptible Intermediate	1 (5.0%)	19 (59.4%)
	Resistant	19 (95.0%)	13 (40.6%)
MOXIFLOXACIN b	Susceptible	17 (85.0%)	30 (93.8%)
	Intermediate Resistant	3 (15.0%)	1 (3.1%)
TETRACYCLINE a	Susceptible Intermediate	3 (15.0%)	3 (9.4%)
	Resistant	17 (85.0%)	29 (90.6%)
	Susceptible	18 (90.0%)	32 (100.0%)
TIGECYCLINE a	Intermediate Resistant	1 (5.0%) 1(5.0%)	-
			I
PENICILLIN a	Susceptible Intermediate	1 (5.0%)	15 (46.9%)
	Resistant	19 (95.0%)	17 (53.1%)
TRIMETHOPRIM/ SULPHAMETHOXAZOLE a	Susceptible	17 (85.0%)	31 (96.9%)
	Intermediate Resistant	3 (15.0%)	1 (3.1%)
			,
VANCOMYCIN a	Susceptible Intermediate	15 (75.0%)	21 (65.6%)
	Resistant	5 (25.0%)	11 (34.4%)

# Conclusion

This study demonstrated the increasing resistance of *S. agalactiae* and E. faecalis to the antimicrobials commonly administered for their eradication and highlights the need for alternative treatment regimens for AV during pregnancy to reduce the risk of (AV-associated) negative pregnancy outcomes.

# Acknowledgements

This study was funded by the National Research Foundation of South Africa. We would like to express our gratitude to the women who agreed to participate in this study and to Prof. Sue Fawcus who facilitated sample collection. We gratefully acknowledge the ICAN for making the presenter's conference attendance possible.

# References

Donati, L., Di Vico, A., Nucci, M., Quagliozzi, L., Spagnuolo, T., Labianca, A., Bracaglia, M., Ianniello, F., Caruso, A.m., and Paradisi, G. (2010). Vaginal microbial flora and outcome of pregnancy. Arch Gynecol Obstet, 281: 589 - 600.

Li, L., Hain-ing, Y., and Jianrong, S. (2011). Vaginal lactobacillus distributions and functions in pregnant women. Afr J Microbiol Res, 5 (10): 1224-1230.

Mijac, V. D., Dukic, S. V., Opavski, N., Dukic, M. K., Ranin, L. T. (2006). Hydrogen peroxide producing lactobacilli in women with vaginal infections. European J Obstet, Gynecol and Reprod Biol, 129:69-76.

Stojanovic, N., Plecas, D., and Plesinac, S. (2012). Normal vaginal flora, disorders and application of probiotics in pregnancy. Arch Gynecol Obstet, 286: 325 – 332.

World Medical Association Declaration of Helsinki (2013). Ethical Principles for Medical Research Involving Human Subjects. J Amer Med Assoc, 310: 2191-2194.